Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 62Phase 1/2 41Phase 3 5Phase 2/3 4Phase EARLY_PHASE1 2Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Pathologic Processes 1Neoplasms 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

nilotinib 12Imatinib Mesylate 11Dasatinib 3ruxolitinib 2posaconazole 2fludarabine 2bosutinib 2asciminib 2Cyclophosphamide 2Busulfan 2zanubrutinib 1trametinib 1pegaspargase 1flumatinib 1fludarabine phosphate 1eltrombopag 1dabrafenib 1avapritinib 1Thiotepa 1Rituximab 1Radiotherapy 1Phlebotomy 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Micafungin 1Interferons 1Idarubicin 1Hydroxyurea 1Growth Hormone 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Azacitidine × Myeloid × Clear all
NCT01201811 2019-12-05

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Celgene

Phase 4 Completed
44 enrolled 26 charts
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Neoplasms, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡